Antiangiogenic Peptides: From Lab Tools to Approved Cancer Drugs

This is a comprehensive narrative review covering the field of antiangiogenic peptides and proteins as of 2006. The authors reviewed preclinical studies, clinical trial data, and approved drugs across multiple molecular classes: cytokines, chemokines, antibodies, soluble receptors, extracellular matrix fragments, and synthetic peptides. For each class, they discussed mechanisms of action, preclinical evidence, clinical development status, and therapeutic potential.

This review captures a pivotal moment in cancer therapy — the transition of antiangiogenic peptides from laboratory curiosities to approved drugs that changed patient outcomes. The approval of bevacizumab proved that starving tumors of blood supply could be a viable cancer treatment strategy, opening the door to dozens of antiangiogenic drugs that followed. Understanding the peptide origins of this drug class helps contextualize why peptide-based approaches remain central to cancer drug development.

Antiangiogenic therapy has become one of the pillars of modern cancer treatment alongside chemotherapy, immunotherapy, and targeted therapy. What began with peptide and protein research — understanding how fragments of extracellular matrix proteins naturally inhibit blood vessel growth — has grown into a multi-billion dollar drug class. Bevacizumab alone has been approved for multiple cancer types and generates billions in annual revenue. The peptide origin of these therapeutics demonstrates how basic peptide biology can directly lead to transformative cancer drugs.

As a review from 2006, this paper does not cover many drugs and discoveries that came after its publication, including many antiangiogenic drugs that have since been approved or failed in trials. Some of the clinical trials discussed were still ongoing and their outcomes may have differed from expectations. The optimism about certain peptide candidates may not have been borne out by subsequent clinical results. The field has also learned that antiangiogenic resistance is a major clinical challenge.